How will congressional election outcomes affect cannabis reform?
The midterm congressional election will have significant implications for federal cannabis reform efforts, reports Marijuana Moment.
The publication highlights that the Democrats may not retain majorities in the House of Representatives and the Senate, however, alternative outcomes will not necessarily be negative for cannabis reform in the coming year.
Marijuana Moment explores what people can expect for cannabis under each outcome, including if:
- Republicans take the House, Democrats keep the Senate
- Republicans take the House and Senate
- Democrats keep the House and Senate
- Republicans take the Senate, Democrats keep the House
Enjoy Cannabis Daily each morning at 8 a.m.
A REAL ONE
Cookies CEO on empowering legacy operators
MJ Biz Daily speaks to rapper and cannabis entrepreneur, Berner, CEO of iconic cannabis brand Cookies, about the industry and how he built the Cookies brand.
Discussing paying homage to small-batch growers, empowering legacy cultivators, operators and breeders and the reason Cookies was successful in the clothing space, Berner tells the publication that respect must be paid to “the real people in the industry.”
“There’s a lot of moving parts that keep the real ones in the game, and it’s going to take a lot of work from everyone to make that happen,” said Berner.
Canadian company ‘well positioned’ to capture part of the Missouri market
Toronto-based Heritage Cannabis Holdings has announced that the recent vote to legalize cannabis in Missouri is expected to have positive impacts on its recently launched U.S. strategy to enter medical and recreational legalized states in the U.S., reports the Financial Post.
Stating it aims to become a market leader in the state, the company will be using an asset light approach in partnership with existing local license holders. David Schwede, CEO of Heritage, told the publication: “Missouri is expected to see strong growth as legalization takes shape and Heritage is well positioned to capture a piece of this burgeoning medical and recreational market. Our leadership team is focused heavily on the State and the opportunities that it presents the Company.”
EU STOCK REVIEW
Jazz Pharma scraps US Sativex trial, & IM Cannabis pulls out of Canada
BusinessCann reports on the latest European stock updates.
This week’s update includes:
- Jazz Pharmaceuticals, which has said it planned to abandon trials to have its flagship cannabis compound Sativex approved in the US.
- IM Cannabis, which saw stock drop over 15% this week after announcing plans to exit ‘the Canadian cannabis market’ and instead focus its resources on opportunities in ‘Israel, Germany and Europe’.
- Panaxia Labs, which also saw its share price fall this week amid news that its Chief Financial Officer Sigal Ben Ali was due to depart the company after less than a year on the job.